Digging into the results for Astrazeneca's CALYPSO Phase III trial of eneboparatide (AZP-3601) in chronic hypoparathyroidism

Executed on:Jun 20, 2025 1:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Children's Hospital of Philadelphia

Chief Emeritus of Endocrinology and Diabetes and Director of the Center for Bone Health at The Children’s Hospital of Philadelphia &  Professor Emeritus of Pediatrics and Medicine at the University of Pennsylvania Perelman School of Medicine. 
Research interests focus on the genetic basis of endocrine signaling defects; his approach is to apply molecular and genetic tools to analyze the basis of altered hormone action, particularly in G protein-coupled signal transduction systems that affect growth and development. 
Identified the molecular basis of several inherited disorders of mineral metabolism, including familial hypoparathyroidism, pseudohypoparathyroidism, and the McCune Albright syndrome. 

Interview Goal

On this call we will discuss the clinical significance and therapeutic potential of eneboparatide (AZP-3601) in treating chronic hypoparathyroidism, following its positive results in the CALYPSO Phase III trial. We aim to better understand how this investigational PTH receptor agonist compares to standard therapies in terms of efficacy, safety, and long-term disease management.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.